• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Clinical Trial Diversity: Pharma Takes Action to Address Disparities

by Fred Pennic 06/26/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Lisa Bailey, Managing Director & Head of DEI Strategy at Trinity Life Sciences

What You Should Know: 

– Trinity Life Sciences, a leader in global life sciences commercialization solutions, has released a new white paper titled “Diversity in Clinical Trials: Life Sciences Initiatives and Challenges in Light of the FDA’s Latest Guidance.” 

– The paper sheds light on the critical issue of racial and ethnic diversity in clinical trials, exploring current industry initiatives, their effectiveness, and the future landscape shaped by the FDA’s evolving guidance.

The Importance of Diversity in Clinical Research

The research emphasizes the importance of diverse clinical trial populations in achieving equitable healthcare. When a wider range of racial and ethnic backgrounds are represented in trials, the resulting treatments are more likely to be effective for the entire population they are intended to serve.

Barriers to Diverse Participation

A significant finding is that one-third of executives interviewed by Trinity identified mistrust in the healthcare system as a major obstacle to achieving diversity. This mistrust stems from historical abuses in clinical trials and negative experiences with traditional healthcare. Concerns about the quality of care received during trials and lingering anxieties based on past injustices contribute to a reluctance, particularly among lower socioeconomic communities, to participate in research.

The Role of the FDA

The paper highlights the US Food and Drug Administration’s (FDA’s) role in shaping the future of clinical trial diversity. In 2022, the FDA released draft guidance outlining strategies for pharmaceutical companies to improve participation from underrepresented racial and ethnic groups in clinical trials. As the FDA finalizes these guidelines, pharmaceutical companies are expected to continue prioritizing investments in diversity initiatives.

Industry Initiatives: Three Key Areas

The research identifies three key areas where pharmaceutical companies are focusing their efforts to improve clinical trial diversity:

  • Collaboration: This includes working with multicultural communities, establishing Diversity Centers of Excellence, and collaborating with a wider healthcare ecosystem – regulators, patients, and other biopharma companies – to create meaningful progress. Strategic partnerships with non-profit organizations focused on health equity are also gaining traction.
  • Strategic Realignment: Companies are reviewing and updating their processes to capture and analyze demographic data on race and ethnicity. A commitment to designing trials that reflect the communities they serve is also crucial. Diversity goals are being established based on the disease’s epidemiology.
  • Investment: This encompasses contributions to industry-wide partnerships, developing tools to measure diversity efforts, and building strong relationships with community-based organizations that serve underserved populations.

“Identifying opportunities to promote inclusive participation in clinical trials is a multifaceted, challenging effort, yet it is critical to ensure representation,” explained Lisa Bailey, Managing Director & Head of DEI Strategy at Trinity Life Sciences. “The findings in this new research outline actions life sciences companies are taking to manage the inherent challenges in achieving diversity in clinical trials, and ultimately, to improve health equity.” 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |